1150-90-9

Basic information

• Product Name: Estratetraenol
• Synonyms: Estra-1,3,5(10),16-Tetraen-3-Ol;Estratetraenol;(8S,9S,13S,14S)-13-methyl-6,7,8,9,11,12,14,15-octahydrocyclopenta[a]ph enanthren-3-ol;1,3,5(10),16-Estratetren-3-ol;1,3,5(10),16-Estratetraen-3-ol;(8S,9S,13R,14S)-13-methyl-6,7,8,9,11,12,14,15-octahydrocyclopenta[a]phenanthren-3-ol;CoMpound 742;ESTRA-1,3-5(10),16-TERAEN-3-OL
• CAS NO: 1150-90-9
• Molecular Formula: C₁₈H₂₂O
• Molecular Weight: 254.37
• Product Categories: Steroids
• Mol File: 1150-90-9.mol
• Article Data: 12

Chemical Properties

• Melting Point: 130-131.5 °C
• Boiling Point: 400.2 °C at 760mmHg
• Flash Point: 180.6 °C
• Appearance: /
• Density: 1.111 g/cm³
• Vapor Pressure: 5.59E-07mmHg at 25°C
• Refractive Index: 1.592
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
• PKA: 14.03±0.40(Predicted)
• CAS DataBase Reference: Estratetraenol(CAS DataBase Reference)
• NIST Chemistry Reference: Estratetraenol(1150-90-9)
• EPA Substance Registry System: Estratetraenol(1150-90-9)

Safety Data

• Hazardous Substances Data: 1150-90-9(Hazardous Substances Data)

Usage

Chemical Properties

Yellow Solid

Uses

A steroid produced by females having pheromone activities.

Definition

ChEBI: A 3-hydroxy steroid that is obtained by formal dehydration at the 17-position of estradiol.

InChI:InChI=1/C18H22O/c1-18-9-2-3-17(18)16-6-4-12-11-13(19)5-7-14(12)15(16)8-10-18/h2,5,7,9,11,15-17,19H,3-4,6,8,10H2,1H3/t15-,16-,17+,18+/m1/s1

Upstream product

• 23880-57-1 (8S,9S,13R,14S)-3-(benzyloxy)-13-methyl-7,8,9,11,12,13,14,15-octahydro-6H-cyclopenta[a]phenanthrene 
• 55105-93-6 estrone p-toluenesulfonylhydrazone 
• 50-28-2 estradiol 
• 53-16-7 Estrone 

Downstream Products

• 1316291-21-0 (8R,9S,13S,14S)-3-(benzyloxy)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-16,17-diol 
• 23880-57-1 (8S,9S,13R,14S)-3-(benzyloxy)-13-methyl-7,8,9,11,12,13,14,15-octahydro-6H-cyclopenta[a]phenanthrene 
• 472-56-0 Estroxide 

Relevant articles and documents

A pharmaceutical composition containing 2-hydroxy-7-methyl octahydrophenanthrene derivative as an estrogen receptor ligand or a pharmaceutically acceptable salt thereof as an effective component

Provided are a compound represented by chemical formulas I and II, or a pharmaceutically acceptable ester, amide, or carbamate salt thereof; and a solvent compound comprising a solvent compound of the ester, amide, or carbamate salt thereof. In addition, provided are use of the compound in treating or preventing diseases or disorders related to activation of an estrogen receptor, and a pharmaceutical composition comprising the compound. In chemical formulas I and II, definitions of R_1, R_2, R_3, and R_4 are the same as those in the specification.COPYRIGHT KIPO 2016

Androstane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods

The invention relates to a method of altering hypothalamic function in an individual. The method comprises nasally administering a human semiochemical, e.g. an Androstane steroid, or a pharmaceutical composition containing a semiochemical, such that the ligand semiochemical binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers. Other embodiments of the invention include pharmaceutical compositions containing the steroids.

Steroids as neurochemical stimulators of the VNO to alleviate pain

The invention relates to a method of alleviating pain. The method comprises nasally administering a steroid which is a human vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor. The steroid or steroids is/are preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.